^
Association details:
| Biomarker: | IDH1 R132H |
|---|---|
| Cancer: | Glioma |
| Drug: | temozolomide (DNA synthesis inhibitor) + azacitidine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
Excerpt:
In vivo, 5-aza treatment extended survival in IDH1 R132H mutant but not in an IDH1 wt glioma model. Additionally, 5-aza enhances the therapeutic effect of the DNA damaging agent TMZ in both subcutaneous and orthotopic PDX models of IDH1 R132H mutant glioma....5-Aza provided a survival benefit as a single agent but worked best in combination with TMZ in 2 different IDH1 R132H mutant glioma models.
DOI:
10.1093/neuonc/noy146
